Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;4(2):107-10.
doi: 10.14283/jfa.2015.48.

EFFECT OF SELENIUM SUPPLEMENTATION ON PROTEOMIC SERUM BIOMARKERS IN ELDERLY MEN

A M Algotar  1 , R Behnejad  2 , P Singh  3 , P A Thompson  4 , C H Hsu  5 , S P Stratton  2
Affiliations

EFFECT OF SELENIUM SUPPLEMENTATION ON PROTEOMIC SERUM BIOMARKERS IN ELDERLY MEN

A M Algotar et al. J Frailty Aging. 2015.

Abstract

Objectives: To determine the effect of selenium supplementation on the human proteomic profile.

Design: Serum samples were collected in this pilot study from a randomized placebo controlled Phase 2 clinical trial (Watchful Waiting (WW)).

Setting: Subjects were followed every three months for up to five years at the University of Arizona Prostate Cancer Prevention Program.

Participants: One hundred and forty men (age < 85 years) had biopsy-proven prostate cancer, a Gleason sum score less than eight, no metastatic cancer, and no prior treatment for prostate cancer.

Intervention: As part of the WW trial, men were randomized to placebo, selenium 200 μg/day or selenium 800 μg/day. For the purpose of the current study, 40 subjects enrolled in the WW study (20 from the placebo group and 20 from Se 800 μg/day group) were selected.

Measurements: Baseline serum samples were collected at each follow-up visit and stored at -80 degrees Celsius. A multiplexed proteomic panel investigated changes in 120 proteins markers simultaneously.

Results: Thirteen proteins (Apolipoprotein J, IL-10, IL-1 alpha, MMP-3, IL-12p70, IL-2 receptor alpha, cathepsin B, eotaxin, EGFR, FGF-basic, myeloperoxidase, RANTES, TGF-beta) were determined to be either statistically (p-value < 0.05) or marginally significantly (0.05 < p-value <0.1) changed in the selenium supplemented group as compared to placebo.

Conclusion: Although independent validation of these results is needed, this study is the first of its kind to utilize high throughput fluorescence based protein multiplex panel in analyzing changes in the proteomic profile due to selenium supplementation. Results from this study provide insight into the ability of selenium to modulate numerous protein markers and thus impact various biological processes in humans.

Keywords: Selenium supplementation; elderly men; proteomic biomarkers.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: All authors declare that there are no competing interests to declare. Dr. Amit Algotar reports grants from National Cancer Institute, during the conduct of the study. Roxanna Behnejad has nothing to disclose. Dr. Parminder Singh has nothing to disclose. Dr. Patricia Thompson has nothing to disclose. Dr. C.H. Hsu has nothing to disclose. Dr. Steven Stratton reports grants from National Cancer Institute, during the conduct of the study.

References

    1. Rayman MP. The importance of selenium to human health. Lancet. 2000;356:233–241. - PubMed
    1. Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal. 2007;9:775–806. - PubMed
    1. Stratton MS, Reid ME, Schwartzberg G, Minter FE, Monroe BK, Alberts DS, Marshall JR, Ahmann FR. Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the ‘Watchful Waiting’ Study. Anticancer Drugs. 2003;14:595–600. - PubMed
    1. Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH, Hsu CH, Thompson PA, Clark LC, Ahmann FR. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res. 2010;3:1035–1043. - PMC - PubMed
    1. Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J. Apolipoprotein J (clusterin) and Alzheimer’s disease. Microsc Res Tech. 2000;50:305–315. - PubMed